See more : lastminute.com N.V. (LMN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of DexCom, Inc. (DXCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DexCom, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Götenehus Group AB (publ) (GHUS-B.ST) Income Statement Analysis – Financial Results
- Lumina Gold Corp. (LMGDF) Income Statement Analysis – Financial Results
- Lakhotia Polyesters (India) Limited (LAKHOTIA.BO) Income Statement Analysis – Financial Results
- DRB-HICOM Berhad (1619.KL) Income Statement Analysis – Financial Results
- Redx Pharma Plc (REDX.L) Income Statement Analysis – Financial Results
DexCom, Inc. (DXCM)
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B | 1.03B | 718.50M | 573.30M | 402.00M | 259.20M | 160.00M | 99.90M | 76.27M | 48.63M | 29.69M | 9.84M | 4.63M | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33B | 1.03B | 768.00M | 646.60M | 544.50M | 367.70M | 226.40M | 194.90M | 123.60M | 82.90M | 59.90M | 53.30M | 40.42M | 30.19M | 26.03M | 15.37M | 12.74M | 10.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.29B | 1.88B | 1.68B | 1.28B | 931.50M | 663.90M | 492.10M | 378.40M | 278.40M | 176.30M | 100.10M | 46.60M | 35.84M | 18.44M | 3.66M | -5.53M | -8.11M | -8.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 63.19% | 64.72% | 68.63% | 66.44% | 63.11% | 64.36% | 68.49% | 66.00% | 69.25% | 68.02% | 62.56% | 46.65% | 47.00% | 37.92% | 12.33% | -56.20% | -175.25% | -405.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 505.80M | 484.20M | 604.20M | 359.90M | 273.50M | 417.40M | 185.40M | 156.10M | 137.50M | 69.40M | 44.80M | 39.50M | 30.75M | 23.23M | 14.29M | 19.63M | 16.13M | 19.42M | 26.77M | 12.47M | 8.93M | 6.31M | 5.04M | 2.90M |
| General & Administrative | 1.00B | 867.20M | 684.10M | 544.20M | 482.60M | 408.80M | 327.30M | 274.30M | 194.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 180.80M | 133.00M | 126.40M | 76.50M | 33.10M | 24.00M | 21.90M | 11.90M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 325.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.19B | 1.00B | 810.50M | 620.70M | 515.70M | 432.80M | 349.20M | 286.20M | 198.00M | 128.40M | 84.20M | 62.80M | 49.94M | 40.51M | 35.20M | 27.67M | 22.44M | 21.11M | 5.66M | 1.60M | 1.25M | 0.00 | 1.69M | 1.11M |
| Other Expenses | 0.00 | 7.50M | -1.70M | 0.00 | 0.00 | 0.00 | 3.40M | -700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.69B | 1.49B | 1.41B | 980.60M | 789.20M | 850.20M | 534.60M | 442.30M | 335.50M | 197.80M | 129.00M | 102.30M | 80.69M | 63.73M | 49.49M | 47.30M | 38.57M | 40.53M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Cost & Expenses | 3.02B | 2.52B | 2.18B | 1.63B | 1.33B | 1.22B | 761.00M | 637.20M | 459.10M | 280.70M | 188.90M | 155.60M | 121.11M | 93.92M | 75.53M | 62.67M | 51.30M | 51.49M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Interest Income | 135.00M | 18.00M | 1.70M | 16.10M | 26.40M | 2.40M | 3.30M | 400.00K | 0.00 | 0.00 | 0.00 | 100.00K | 107.00K | 95.00K | 354.00K | 1.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.30M | 18.60M | 102.00M | 84.70M | 60.30M | 22.70M | 12.80M | 700.00K | 400.00K | 800.00K | 900.00K | 200.00K | 11.00K | 1.55M | 8.05M | 7.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 186.00M | 155.90M | 101.90M | 67.10M | 48.70M | 29.10M | 16.10M | 15.00M | 10.80M | 8.40M | 7.00M | 6.60M | 3.76M | 2.44M | 2.37M | 3.58M | 3.33M | 2.70M | 1.07M | 935.49K | 353.55K | 0.00 | 0.00 | 0.00 |
| EBITDA | 916.70M | 565.30M | 377.50M | 376.80M | 213.20M | -74.70M | -19.70M | -49.20M | -46.30M | -13.10M | -21.90M | -49.00M | -40.98M | -51.19M | -43.11M | -49.79M | -43.34M | -46.62M | -29.70M | -13.13M | -9.83M | -6.31M | -6.72M | -4.01M |
| EBITDA Ratio | 25.31% | 14.33% | 11.33% | 19.86% | 11.14% | -10.06% | -4.98% | -11.20% | -14.20% | -8.29% | -13.69% | -49.05% | -53.87% | -70.79% | -146.36% | -500.90% | -936.76% | -2,148.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 597.70M | 391.20M | 175.40M | 299.50M | 142.30M | -186.30M | -42.50M | -63.90M | -57.10M | -21.50M | -28.90M | -55.70M | -44.84M | -45.29M | -45.83M | -52.83M | -46.68M | -49.32M | -32.43M | -14.07M | -10.18M | -6.31M | -6.72M | -4.01M |
| Operating Income Ratio | 16.50% | 13.44% | 7.16% | 15.54% | 9.64% | -18.06% | -5.92% | -11.15% | -14.20% | -8.29% | -18.06% | -55.76% | -58.80% | -93.13% | -154.36% | -536.97% | -1,008.77% | -2,273.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 112.70M | -400.00K | -9.00M | -74.50M | -38.10M | 59.80M | -6.10M | -1.00M | -400.00K | -800.00K | -900.00K | -100.00K | 97.00K | -9.88M | -7.69M | -2.36M | 798.00K | 2.72M | -30.86B | 120.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 710.40M | 390.80M | 173.90M | 225.00M | 104.20M | -126.50M | -48.60M | -64.90M | -57.50M | -22.30M | -29.80M | -55.80M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 19.61% | 13.43% | 7.10% | 11.68% | 7.06% | -12.26% | -6.76% | -11.32% | -14.30% | -8.60% | -18.63% | -55.86% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 168.90M | 49.60M | 19.20M | -268.60M | 3.10M | 600.00K | 1.60M | 700.00K | 100.00K | 100.00K | 0.00 | -1.30M | -97.00K | 9.88M | 0.00 | 2.36M | 0.00 | 253.00 | -30.86B | -120.65K | -270.00K | 7.71M | 6.27M | 3.97M |
| Net Income | 541.50M | 341.20M | 154.70M | 493.60M | 101.10M | -127.10M | -50.20M | -65.60M | -57.60M | -22.40M | -29.80M | -54.50M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.77M | -13.95M | -9.91M | -7.71M | -6.27M | -3.97M |
| Net Income Ratio | 14.95% | 11.73% | 6.32% | 25.62% | 6.85% | -12.32% | -6.99% | -11.44% | -14.33% | -8.64% | -18.63% | -54.55% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.44 | 0.88 | 0.40 | 1.31 | 0.28 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| EPS Diluted | 1.30 | 0.80 | 0.36 | 1.27 | 0.27 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| Weighted Avg Shares Out | 386.00M | 389.40M | 386.90M | 377.60M | 364.40M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
| Weighted Avg Shares Out (Dil) | 425.50M | 427.50M | 428.80M | 390.00M | 369.20M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
Dexcom and ŌURA Announce Strategic Partnership
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world's leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration...
Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day
SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they're made of. This comes as global data1 shows...
3 Top Stocks for Growth Investors to Buy Now
The undervalued stocks of these mid-sized companies with economic moats look attractive.
1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years
This medical device company is down but not out.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why DexCom Stock Flopped on Friday
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth.
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday.
DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises
DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
DexCom Beats Earnings Expectations. Why the Stock Is Trading Lower.
DexCom's U.S. revenue declines 2% in the third quarter from a year earlier.
Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday.
Source: https://incomestatements.info
Category: Stock Reports